Week's top dermatology reads include Cimzia study, FDA actions

Study results showing minimal to no transfer of Cimzia from mother's plasma to breast milk was a top-read article of the past week on Healio.com/Dermatology.

Other widely-read articles include recent FDA actions including the approval of Dupixent for atopic dermatitis and the addition of fingernail psoriasis data to Humira prescribing information:

Study shows minimal to no transfer of Cimzia from mother's plasma to breast milk

There was minimal to no transfer of Cimzia from nursing mothers to breast milk, considered to be an acceptable range for breast-feeding, according to a poster presentation at the American Academy of Dermatology Annual Meeting in Orlando, Florida.

“It is well-recognized that women with chronic inflammatory diseases face uncertainty during motherhood, given the lack of information on use of therapies that can control their symptoms during breast-feeding,” researcher Megan E.B. Clowse, MD, of Duke University Medical Center, Durham, North Carolina, stated in a news release from UCB. Read more

FDA approves Dupixent for atopic dermatitis

The FDA has approved Dupixent injection to treat adults with moderate-to-severe atopic dermatitis whose disease in not adequately controlled with topical therapies or when those therapies are not advisable.

Dupixent (dupilumab, Regeneron Pharmaceuticals and Sanofi) is the first biologic medicine approved for this indication, according to a press release from Regeneron and Sanofi. It can be used with or without topical corticosteroids. With Perspective. Read more

FDA approves adding fingernail psoriasis data to Humira prescribing information

The FDA has approved including moderate-to-severe fingernail psoriasis data in the Humira prescribing information for patients with moderate-to-severe plaque psoriasis, AbbVie has reported.

Humira (adalimumab, AbbVie) is the first biologic treatment with data on fingernail psoriasis in its U.S. prescribing information, according to a news release from AbbVie. Read more

Hair growth product for alopecia areata debuts at AAD

Eclipse Aesthetics announced its partnership with Theradome to launch a restorative hair device for people with alopecia areata at the American Academy of Dermatology Annual Meeting in Orlando, Florida.

Theradome LH80 Pro, which utilizes 80 proprietary lasers, is FDA cleared for home use, according to a news release. Read more

AAD elects vice president-elect, board members

The American Academy of Dermatology announced the results of its annual election, including Jane M. Grant-Kels, MD, FAAD, as vice president-elect and four new board members.

Grant-Kels is a professor of dermatology, pathology and pediatrics; vice chair of the department of dermatology; director of the cutaneous oncology center and melanoma program; and founding chair emeritus of the dermatology department, dermatology residency program and dermatopathology lab at UConn Health in Farmington, Connecticut. Read more